Sex hormones and frailty in older men: The osteoporotic fractures in men (MrOS) study

Peggy M. Cawthon, Kristine E. Ensrud, Gail A. Laughlin, Jane A. Cauley, Thuy Tien L Dam, Elizabeth Barrett-Connor, Howard A. Fink, Andrew R. Hoffman, Edith Lau, Nancy E Lane, Marcia L. Stefanick, Steven R. Cummings, Eric S. Orwoll

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Context: As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors. Objective: The aim of this study was to assess cross-sectional and longitudinal associations of estradiol, bioavailable estradiol, testosterone, bioavailable testosterone (bioT), and SHBG with frailty status. Design and Setting: The Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. Participants: A total of 1469 community-dwelling men at least 65 yr old with baseline data participated; 1245 men had frailty status reassessed 4.1 yr later. Main Outcome Measure: Proportional odds models estimated the likelihood of greater frailty status. Frail men had at least three of the following: weakness, slowness, low activity, exhaustion, and shrinking/sarcopenia; intermediate men had one or two criteria; and robust men had none. At follow-up, death was included as an additional ordinal outcome. Sex hormones were assayed by spectrometry/chromatographic methods. Results: In cross-sectional analyses, men in the lowest quartile of bioT had 1.39-fold (95% confidence interval, 1.02, 1.91) increased odds of greater frailty status compared to men in the highest quartile after adjustment for covariates including age, body size, health status, and medical conditions. In age-adjusted longitudinal analyses, men in the lowest quartile of bioT had 1.51-fold (95% confidence interval, 1.10, 2.07) increased odds of greater frailty status 4.1 yr later. This association was largely attenuated by adjustment for covariates. No other hormones were associated in a cross-sectional or longitudinal manner with frailty status after adjustment. Conclusions: Low levels of bioT were independently associated with worse baseline frailty status. Frailty status should be considered as an outcome in trials of testosterone supplementation.

Original languageEnglish (US)
Pages (from-to)3806-3815
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Osteoporotic Fractures
Gonadal Steroid Hormones
Testosterone
Estradiol
Spectrometry
Androgens
Confidence Intervals
Sarcopenia
Independent Living
Health
Hormones
Body Size
Health Status
Spectrum Analysis
Cross-Sectional Studies
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Cawthon, P. M., Ensrud, K. E., Laughlin, G. A., Cauley, J. A., Dam, T. T. L., Barrett-Connor, E., ... Orwoll, E. S. (2009). Sex hormones and frailty in older men: The osteoporotic fractures in men (MrOS) study. Journal of Clinical Endocrinology and Metabolism, 94(10), 3806-3815. https://doi.org/10.1210/jc.2009-0417

Sex hormones and frailty in older men : The osteoporotic fractures in men (MrOS) study. / Cawthon, Peggy M.; Ensrud, Kristine E.; Laughlin, Gail A.; Cauley, Jane A.; Dam, Thuy Tien L; Barrett-Connor, Elizabeth; Fink, Howard A.; Hoffman, Andrew R.; Lau, Edith; Lane, Nancy E; Stefanick, Marcia L.; Cummings, Steven R.; Orwoll, Eric S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 10, 2009, p. 3806-3815.

Research output: Contribution to journalArticle

Cawthon, PM, Ensrud, KE, Laughlin, GA, Cauley, JA, Dam, TTL, Barrett-Connor, E, Fink, HA, Hoffman, AR, Lau, E, Lane, NE, Stefanick, ML, Cummings, SR & Orwoll, ES 2009, 'Sex hormones and frailty in older men: The osteoporotic fractures in men (MrOS) study', Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 10, pp. 3806-3815. https://doi.org/10.1210/jc.2009-0417
Cawthon, Peggy M. ; Ensrud, Kristine E. ; Laughlin, Gail A. ; Cauley, Jane A. ; Dam, Thuy Tien L ; Barrett-Connor, Elizabeth ; Fink, Howard A. ; Hoffman, Andrew R. ; Lau, Edith ; Lane, Nancy E ; Stefanick, Marcia L. ; Cummings, Steven R. ; Orwoll, Eric S. / Sex hormones and frailty in older men : The osteoporotic fractures in men (MrOS) study. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 10. pp. 3806-3815.
@article{8c2e86d895b04c739394ce5d5c2a04e7,
title = "Sex hormones and frailty in older men: The osteoporotic fractures in men (MrOS) study",
abstract = "Context: As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors. Objective: The aim of this study was to assess cross-sectional and longitudinal associations of estradiol, bioavailable estradiol, testosterone, bioavailable testosterone (bioT), and SHBG with frailty status. Design and Setting: The Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. Participants: A total of 1469 community-dwelling men at least 65 yr old with baseline data participated; 1245 men had frailty status reassessed 4.1 yr later. Main Outcome Measure: Proportional odds models estimated the likelihood of greater frailty status. Frail men had at least three of the following: weakness, slowness, low activity, exhaustion, and shrinking/sarcopenia; intermediate men had one or two criteria; and robust men had none. At follow-up, death was included as an additional ordinal outcome. Sex hormones were assayed by spectrometry/chromatographic methods. Results: In cross-sectional analyses, men in the lowest quartile of bioT had 1.39-fold (95{\%} confidence interval, 1.02, 1.91) increased odds of greater frailty status compared to men in the highest quartile after adjustment for covariates including age, body size, health status, and medical conditions. In age-adjusted longitudinal analyses, men in the lowest quartile of bioT had 1.51-fold (95{\%} confidence interval, 1.10, 2.07) increased odds of greater frailty status 4.1 yr later. This association was largely attenuated by adjustment for covariates. No other hormones were associated in a cross-sectional or longitudinal manner with frailty status after adjustment. Conclusions: Low levels of bioT were independently associated with worse baseline frailty status. Frailty status should be considered as an outcome in trials of testosterone supplementation.",
author = "Cawthon, {Peggy M.} and Ensrud, {Kristine E.} and Laughlin, {Gail A.} and Cauley, {Jane A.} and Dam, {Thuy Tien L} and Elizabeth Barrett-Connor and Fink, {Howard A.} and Hoffman, {Andrew R.} and Edith Lau and Lane, {Nancy E} and Stefanick, {Marcia L.} and Cummings, {Steven R.} and Orwoll, {Eric S.}",
year = "2009",
doi = "10.1210/jc.2009-0417",
language = "English (US)",
volume = "94",
pages = "3806--3815",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Sex hormones and frailty in older men

T2 - The osteoporotic fractures in men (MrOS) study

AU - Cawthon, Peggy M.

AU - Ensrud, Kristine E.

AU - Laughlin, Gail A.

AU - Cauley, Jane A.

AU - Dam, Thuy Tien L

AU - Barrett-Connor, Elizabeth

AU - Fink, Howard A.

AU - Hoffman, Andrew R.

AU - Lau, Edith

AU - Lane, Nancy E

AU - Stefanick, Marcia L.

AU - Cummings, Steven R.

AU - Orwoll, Eric S.

PY - 2009

Y1 - 2009

N2 - Context: As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors. Objective: The aim of this study was to assess cross-sectional and longitudinal associations of estradiol, bioavailable estradiol, testosterone, bioavailable testosterone (bioT), and SHBG with frailty status. Design and Setting: The Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. Participants: A total of 1469 community-dwelling men at least 65 yr old with baseline data participated; 1245 men had frailty status reassessed 4.1 yr later. Main Outcome Measure: Proportional odds models estimated the likelihood of greater frailty status. Frail men had at least three of the following: weakness, slowness, low activity, exhaustion, and shrinking/sarcopenia; intermediate men had one or two criteria; and robust men had none. At follow-up, death was included as an additional ordinal outcome. Sex hormones were assayed by spectrometry/chromatographic methods. Results: In cross-sectional analyses, men in the lowest quartile of bioT had 1.39-fold (95% confidence interval, 1.02, 1.91) increased odds of greater frailty status compared to men in the highest quartile after adjustment for covariates including age, body size, health status, and medical conditions. In age-adjusted longitudinal analyses, men in the lowest quartile of bioT had 1.51-fold (95% confidence interval, 1.10, 2.07) increased odds of greater frailty status 4.1 yr later. This association was largely attenuated by adjustment for covariates. No other hormones were associated in a cross-sectional or longitudinal manner with frailty status after adjustment. Conclusions: Low levels of bioT were independently associated with worse baseline frailty status. Frailty status should be considered as an outcome in trials of testosterone supplementation.

AB - Context: As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors. Objective: The aim of this study was to assess cross-sectional and longitudinal associations of estradiol, bioavailable estradiol, testosterone, bioavailable testosterone (bioT), and SHBG with frailty status. Design and Setting: The Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. Participants: A total of 1469 community-dwelling men at least 65 yr old with baseline data participated; 1245 men had frailty status reassessed 4.1 yr later. Main Outcome Measure: Proportional odds models estimated the likelihood of greater frailty status. Frail men had at least three of the following: weakness, slowness, low activity, exhaustion, and shrinking/sarcopenia; intermediate men had one or two criteria; and robust men had none. At follow-up, death was included as an additional ordinal outcome. Sex hormones were assayed by spectrometry/chromatographic methods. Results: In cross-sectional analyses, men in the lowest quartile of bioT had 1.39-fold (95% confidence interval, 1.02, 1.91) increased odds of greater frailty status compared to men in the highest quartile after adjustment for covariates including age, body size, health status, and medical conditions. In age-adjusted longitudinal analyses, men in the lowest quartile of bioT had 1.51-fold (95% confidence interval, 1.10, 2.07) increased odds of greater frailty status 4.1 yr later. This association was largely attenuated by adjustment for covariates. No other hormones were associated in a cross-sectional or longitudinal manner with frailty status after adjustment. Conclusions: Low levels of bioT were independently associated with worse baseline frailty status. Frailty status should be considered as an outcome in trials of testosterone supplementation.

UR - http://www.scopus.com/inward/record.url?scp=70349918163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349918163&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-0417

DO - 10.1210/jc.2009-0417

M3 - Article

C2 - 19737923

AN - SCOPUS:70349918163

VL - 94

SP - 3806

EP - 3815

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -